Kathleen Yost is an Oncology physician. OpenAlex indexes 262 publications with 11,388 citations (h-index 48).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
145 Michigan St NE
Suite 3100
Grand Rapids, MI 495032562
Telephone
616-954-9800Provider last certified this registry record 13 Mar 2020.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Pharmacyclics LLC, An AbbVie CompanyProgram year20231 payment
- AstraZeneca Pharmaceuticals LPProgram year20221 payment
- Pharmacyclics LLC, an AbbVie CompanyProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
48.3%Aromatase Inhibitor25%Anastrozole100%Part D≥23 patientsAntimetabolite9.9%Hydroxyurea100%Part D<11 patients+ 2 more classes in this area
Nervous system
14.5%Phenothiazine14.5%Prochlorperazine Maleate100%Part D≥15 patientsDermatology
14%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2001–2004 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
New England Journal of Medicine
2023 - Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant
Biology of Blood and Marrow Transplantation
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”